Mirati Therapeutics' KRAZATI Faces Setback; Comerica Q2 Earnings Beat
- July 21st, 2023
- 255 views
Mirati Therapeutics, Inc. (Nasdaq: MRTX) faced a setback when the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for its drug KRAZATI (adagrasib), intended to treat patients with KRASG12C-mutated advanced non-small cell lung cancer (NSCLC).
According to the CHMP, KRAZATI exhibits a positive risk-benefit profile, but it does not fully meet specific requirements for obtaining Conditional Marketing Authorization. Mirati Therapeutics disagrees with the CHMP's opinion and plans to request a formal re-examination.
In pre-market, $MRTX was trading at $31.54, down $2.27 (-6.71%) following the announcement.
In other news, Comerica Incorporated (NYSE: CMA) released its second-quarter 2023 financial results, exceeding expectations with earnings per share (EPS) of $2.01 compared to the consensus estimate of $1.86.
$CMA was trading at $55.64 in pre-market, reflecting a gain of $2.71 (+5.12%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login